Duke Street Bio

Duke Street Bio is a private, clinical-stage oncology biotech developing novel small molecules targeting DNA Damage Repair (DDR) pathways. Its core technology is centered on creating highly selective PARP1 inhibitors designed to overcome the hematological toxicity limitations of first-generation PARP inhibitors, thereby improving therapeutic index and enabling new combinations. The company's lead candidate, DSB2455, is a potent, CNS-penetrant PARP1 inhibitor in Phase 1a/1b trials, positioning it to potentially expand the treatable patient population in cancers with DDR defects.

Development of highly selective PARP1 inhibitors designed to exploit DNA Damage Repair (DDR) deficiencies in cancer while minimizing hematological toxicity associated with PARP2 inhibition.

Duke Street Bio competes in the crowded PARP inhibitor market dominated by drugs like olaparib (Lynparza) and niraparib (Zejula). Its differentiation is based on PARP1 selectivity to reduce toxicity. It also faces potential competition from other next-generation DDR-targeting therapies and companies exploring PARP1-selective inhibitors, such as IDEAYA Biosciences/GSK with IDE397 (MAT2A inhibitor combo strategy) and other undisclosed preclinical programs.